文献速递肿瘤 PET/CT核素与放射性配体治疗

[177Lu]Lu-PSMA治疗中PSMA-PET疗效评估标准比较

PSMA-PET response under [177Lu]Lu-PSMA therapy: Comparison of RECIST, PERCIST, PPP, adapted PCWG4 and RECIP criteria.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-04-24

该回顾性研究纳入84例接受[177Lu]Lu-PSMA放射性配体治疗的转移性去势抵抗性前列腺癌(mCRPC)患者,比较RECIST 1.1、aPCWG4、PERCIST、PPP及RECIP等标准在基线及第二周期后6–8周PET/CT的疗效评估价值;结果显示各标准判定的进展均与死亡风险升高相关,PPP与aPCWG4同总生存的一致性最高,RECIP的进展率最低。

要点

  • 各评估标准判定的进展均与死亡风险显著升高相关。
  • PPP(C-index 0.68)与aPCWG4(0.67)同总生存一致性最高。
  • RECIP进展率最低,提示需标准化可重复的纵向疗效标准。

核心结论

  • [177Lu]PSMA治疗期间中期PET显示疾病进展(任一评估标准)均与死亡风险升高相关。
  • PPP与aPCWG4同总生存的一致性最高,RECIP的PD率最低。
  • 结果支持PSMA-PET疗效评估的预后价值与一致性,并需在大型前瞻性多中心研究中验证。

研究设计与样本

  • 回顾性研究,纳入2019年3月至2022年5月 Essen 大学医院核医学科84例mCRPC男性。
  • 患者接受中位4个[177Lu]PSMA周期(IQR 2–5),中位剂量24.3 GBq(IQR 14.9–32.9 GBq)。
  • 比较基线PET/CT与第二周期后6–8周PET/CT,采用RECIST 1.1、aPCWG4(不做随访确认)、PERCIST、PPP及RECIP(视觉或qPSMA、SUV ≥ 4定量容积法)。
  • 主要终点为各标准对总生存的预后意义,用Cox回归分析,Harrell C-index评价一致性。

主要发现

  • 34例(40.5%)按RECIST为不可测量病灶。
  • PD比例:RECIST 1.1 20例(40%)、aPCWG4 41例(48.8%)、PERCIST 44例(52.4%)、PPP 47例(56.0%)、RECIP qPSMA 35例(41.7%)、RECIP SUV ≥ 4 37例(44.0%)、视觉RECIP 31例(36.9%)。
  • PD患者死亡风险:RECIST 1.1 HR=5.0(95%CI 2.5–10.0,p<0.001)、PERCIST HR=2.9(95%CI 1.8–4.8,p<0.001)、aPCWG4 HR=3.6(95%CI 2.1–6.0,p<0.001)、PPP HR=3.9(95%CI 2.3–6.6,p<0.001)、RECIP qPSMA HR=2.7(95%CI 1.6–4.4,p<0.001)、RECIP SUV ≥ 4 HR=2.2(95%CI 1.6–3.6,p<0.001)、视觉RECIP HR=3.5(95%CI 2.1–6.0,p<0.001)。
  • C-index:PPP 0.68(95%CI 0.58–0.77)、aPCWG4 0.67(95%CI 0.57–0.77)、PERCIST 0.65(95%CI 0.54–0.75)、视觉RECIP 0.63(95%CI 0.52–0.73)、RECIP qPSMA 0.62(95%CI 0.51–0.74)、RECIP SUV ≥ 4 0.62(95%CI 0.50–0.73)。

关键数值与推荐

  • RECIST 1.1判定的PD患者死亡风险HR=5.0(95%CI 2.5–10.0,p<0.001),为各标准中最高。
  • PPP的C-index为0.68(95%CI 0.58–0.77),aPCWG4为0.67(95%CI 0.57–0.77)。
  • 视觉RECIP的PD率最低,为31例(36.9%)。

临床怎么用

  • [177Lu]PSMA治疗期间可用中期PSMA-PET评估疗效,任一标准判定进展均提示死亡风险升高。
  • PPP与aPCWG4同总生存一致性较高,可优先考虑用于预后分层。
  • RECIP判定的进展率较低,解读时应结合其他标准与临床情况。

局限性

  • 为单中心回顾性研究,样本量84例。
  • aPCWG4未做随访确认,评估时间点为第二周期后6–8周。
  • 作者指出需在大型前瞻性多中心研究中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We aimed to compare various imaging-based response criteria in men with metastatic castration-resistant prostate cancer (mCRPC) treated with [177Lu]Lu-Prostate-specific membrane antigen radioligand therapy (LuPSMA). METHODS: This retrospective study included 84 men who received a median of 4 [177Lu]PSMA cycles (IQR 2–5) and median of 24.3 GBq (IQR 14.9–32.9 GBq) at the Department of Nuclear Medicine at University Hospital Essen between March 2019 and May 2022. Response assessments were conducted comparing baseline PET/CT and PET/CT at 6–8 weeks after second cycle of LuPSMA using multiple criteria: Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, the adapted Prostate Cancer Working Group Criteria 4 (aPCWG4) without follow-up confirmation, Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST), the PSMA PET Progression (PPP), and Response Evaluation Criteria in PSMA-Imaging 1.0 (RECIP) with visual assessment or different quantitative volumetry methods (qPSMA, SUV ≥ 4). Responses were categorized as progressive disease (PD) or non-PD. The primary endpoint was the prognostic significance of these response criteria for overall survival, evaluated via Cox regression analysis. Harrell`s C-index was used for concordance of different imaging-based criteria and survival. RESULTS: A total of 34 (40.5%) patients had non-measurable disease according to RECIST. Twenty (40%), 41 (48.8%), 44 (52.4%), 47 (56.0%), 35 (41.7%), 37 (44.0%), and 31 (36.9%) of patients had PD according to RECIST 1.1, aPCWG4, PERCIST, PPP, RECIP qPSMA, RECIP SUV ≥ 4, and visual RECIP respectively. PD patients had a significantly higher risk of death compared to non-PD patients according to all response criteria as follows: RECIST 1.1 (HR = 5.0; 95%CI, 2.5–10.0; p < 0.001), PERCIST (HR = 2.9; 95%CI, 1.8–4.8; p < 0.001), aPCWG4 (HR = 3.6; 95%CI, 2.1–6.0; p < 0.001), PPP (HR = 3.9; 95%CI, 2.3–6.6; p < 0.001), RECIP qPSMA (HR = 2.7; 95%CI, 1.6–4.4; p < 0.001), RECIP SUV ≥ 4 (HR = 2.2; 95%CI, 1.6–3.6; p < 0.001) and visual RECIP (HR = 3.5; 95%CI, 2.1–6.0; p < 0.001). Highest C-indices were observed for PPP: 0.68 (95%CI, 0.58–0.77), and aPCWG4: 0.67 (95%CI, 0.57–0.77) in comparison to PERCIST: 0.65 (95%CI, 0.54–0.75), visual RECIP: 0.63 (95%CI, 0.52–0.73), RECIP qPSMA: 0.62 (95%CI, 0.51–0.74) and, RECIP SUV ≥ 4: 0.62 (95%CI, 0.50–0.73). CONCLUSION: Disease progression during [177Lu]PSMA in interim PET imaging, as indicated by any of the evaluated criteria, was associated with elevated risk of death. PSMA PET Progression (PPP) and aPCWG4 demonstrated the highest concordance with overall survival whereas RECIP had lowest PD rate. These findings support the prognostic value and consistency of PSMA-PET response assessment during [177Lu]PSMA and highlight the need for standardized, reproducible longitudinal response criteria and support their validation in large, prospective multicenter studies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-026-07901-7.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Telli T, Karpinski MJ, Seifert R, et al. PSMA-PET response under [177Lu]Lu-PSMA therapy: Comparison of RECIST, PERCIST, PPP, adapted PCWG4 and RECIP criteria. Eur J Nucl Med Mol Imaging. 2026. PMID: 42026185. doi:10.1007/s00259-026-07901-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。